A population-based study from Manitoba further showed that initiation of anti-TNF treatment in the first two years following a diagnosis of Crohn’s disease was associated with 4.5 fewer IBD-specific hospitalizations (95% CI: 2.10), and 10.4 fewer all-cause hospitalizations (95% CI: 3.7, 17.0) per 100 person-years, over the five years following the start of therapy (13). The gene discussed is TNF; the disease is Crohn disease.